| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BIRT-377 targets LFA-1 (integrin αLβ2) by binding to its I-domain. It acts as a negative allosteric modulator, inhibiting the interaction between LFA-1 and its ligand ICAM-1 (intercellular adhesion molecule-1). The compound has a Ki of 25.8 nM and a Kd of 26 nM.
|
|---|---|
| ln Vitro |
In vitro, BIRT-377 reversibly inhibits LFA-1 mediated binding of SKW3 leukemia cells to ICAM-1. It inhibits superantigen (SEB)-induced IL-2 production from lymphocytes. It has been shown to inhibit IL-2 production, making it useful for studying inflammatory and immune disorders.
|
| ln Vivo |
In vivo, BIRT-377 attenuates the SEB-induced increase in IL-2 plasma levels in a mouse model. It is orally bioavailable, allowing for convenient administration in animal studies. Its effects on immune function have been demonstrated in vivo.
|
| Enzyme Assay |
The binding of BIRT-377 to LFA-1 can be assessed using surface plasmon resonance (SPR) or radioligand binding assays. The compound is incubated with recombinant LFA-1 protein, and the binding affinity (Kd or Ki) is determined. The Ki of 25.8 nM and Kd of 26 nM have been reported.
|
| Cell Assay |
The cellular activity of BIRT-377 is evaluated using cell adhesion assays. SKW3 leukemia cells are incubated with ICAM-1 in the presence or absence of the compound, and the extent of cell adhesion is measured. The compound's ability to inhibit IL-2 production from lymphocytes is assessed by treating cells with SEB and measuring IL-2 levels in the supernatant.
|
| Animal Protocol |
In vivo studies with BIRT-377 involve administration to mice via oral gavage. In the SEB-induced IL-2 production model, mice are treated with the compound and then challenged with SEB. Plasma levels of IL-2 are measured to assess the compound's efficacy.
|
| ADME/Pharmacokinetics |
BIRT-377 has a molecular formula of C18H15BrCl2N2O2 and a molecular weight of 442.14. It is a small molecule inhibitor with a Ki of 25.8 nM for LFA-1. It is orally bioavailable.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for BIRT-377 are not detailed in the available literature. However, its oral bioavailability and in vivo efficacy in mouse models suggest it is tolerated at effective doses. As with all research compounds, standard safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
BIRT-377 is a research tool for studying the role of LFA-1/ICAM-1 interactions in inflammatory and immune disorders. It is a negative allosteric modulator of LFA-1 and is orally bioavailable. It is not a clinically approved drug but is valuable for preclinical research.
|
| Molecular Formula |
C18H15N2O2CL2BR
|
|---|---|
| Molecular Weight |
442.1339
|
| Exact Mass |
439.969
|
| CAS # |
213211-10-0
|
| PubChem CID |
9803375
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
518.8±60.0 °C at 760 mmHg
|
| Flash Point |
267.6±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
4.76
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@]1(C(=O)N(C(=O)N1C)C2=CC(=CC(=C2)Cl)Cl)CC3=CC=C(C=C3)Br
|
| InChi Key |
FJNJHZQMQRVZEE-GOSISDBHSA-N
|
| InChi Code |
InChI=1S/C18H15BrCl2N2O2/c1-18(10-11-3-5-12(19)6-4-11)16(24)23(17(25)22(18)2)15-8-13(20)7-14(21)9-15/h3-9H,10H2,1-2H3/t18-/m1/s1
|
| Chemical Name |
(5R)-5-[(4-bromophenyl)methyl]-3-(3,5-dichlorophenyl)-1,5-dimethylimidazolidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~226.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2618 mL | 11.3089 mL | 22.6178 mL | |
| 5 mM | 0.4524 mL | 2.2618 mL | 4.5236 mL | |
| 10 mM | 0.2262 mL | 1.1309 mL | 2.2618 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
